US OptionsDetailed Quotes
TSHA241018C2500
- 0.10
- -0.02-16.67%
15min DelayClose Oct 2 16:00 ET
0.15High0.10Low
0.15Open0.12Pre Close4 Volume2.71K Open Interest2.50Strike Price50.00Turnover142.99%IV26.83%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.3017Delta0.5773Gamma20.50Leverage Ratio-0.0069Theta0.0002Rho6.18Eff Leverage0.0015Vega
Taysha Gene Therapies Stock Discussion
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies (Nasdaq: TSHA) has announced a public offering of up to $75 million in common stock and pre-funded warrants. This offering allows certain investors the option to purchase pre-funded warrants instead of common stock. Additionally, underwriters Jefferies, Goldman Sachs, and Cantor have a 30-day option to buy up to 15% more shares under the same...
3 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
Company to host webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time
Oral presentation by Elsa Rossignol, M.D., FRCP, FAAP, Principal Investigator of the REVEAL adolescent and adult trial at CHU Sainte-Justine and Colleen Buhrf...
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (Rmat) Designation Granted by U.S. FDA for Tsha-102 in Rett Syndrome
No comment yet